Publication number: 20090270350
Abstract: This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxyge?ase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R1, R2a, R2b, R2c, R2d, R2e, R3a, R3b, R3c, R3d, R4, R5, R6, R7a, R7b, R7c, R7d and R7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
Type:
Application
Filed:
February 5, 2007
Publication date:
October 29, 2009
Inventors:
Balekudru Devadas, Susan J. Hartmann, Richard F. Heier, Kevin D. Jerome, Steve A. Kolodziej, John Mathias, Monica B. Norton, Michele A. Promo, Paul V. Rucker, Shaun Selness
Publication number: 20070088033
Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
Type:
Application
Filed:
September 13, 2006
Publication date:
April 19, 2007
Inventors:
Balekudru Devadas, John Walker, Shaun Selness, Terri Boehm, Richard Durley, Rajesh Devraj, Brian Hickory, Paul Rucker, Kevin Jerome, Heather Madsen, Edgardo Alvira, Michele Promo, Radhika Blevis-Bal, Laura Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey Shieh, Aruna Sambandam, Shuang Liu, Ian Scott, Kevin McGee
Publication number: 20060211694
Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
Type:
Application
Filed:
September 14, 2005
Publication date:
September 21, 2006
Applicant:
Pharmacia Corporation, Global Patent Department
Inventors:
Balekudru Devadas, John Walker, Shaun Selness, Terri Boehm, Richard Durley, Rajesh Devraj, Brian Hickory, Paul Rucker, Kevin Jerome, Heather Madsen, Edgardo Alvira, Michele Promo, Radhika Blevis-Bal, Laura Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey Shieh, Aruna Sambandam, Shuang Liu, Ian Scott, Kevin McGee